AST blood test
Aspartate aminotransferase. Also called: SGOT, Aspartate transaminase, GOT
AST is an enzyme found in the liver, heart, muscle and red blood cells. It rises when any of these is damaged, so it is read together with ALT: the AST/ALT ratio helps tell liver, muscle and alcohol-related causes apart.
At a glance
| What it measures | Aspartate aminotransferase, an enzyme in liver, heart, muscle and red cells that leaks into the blood when those cells are damaged. |
|---|---|
| Sample | Blood (serum or heparin plasma). Hemolyzed samples are rejected by Quest. No fasting is listed. |
| Typical adult range | Labcorp sample reports: 0-40 IU/L. Quest: men 20-49 years 10-40 U/L, women 20-44 years 10-30 U/L. |
| Common reasons it reads high | Fatty liver, alcohol, viral hepatitis, medications, heavy exercise or muscle injury, a hemolyzed sample, macro-AST. |
| Peptides that move it | Lowered in fatty-liver trials by Semaglutide, Tirzepatide and Survodutide. Label-listed rises with Pasireotide, Degarelix and Triptorelin. |
| Lab code | LOINC 1920-8 (Labcorp 001123, Quest 822) |
What is AST?
Aspartate aminotransferase (AST, formerly called SGOT) is an enzyme that shuffles nitrogen between amino acids, part of protein metabolism and of making new glucose. It is found, in decreasing amounts, in heart, liver, skeletal muscle, kidney, pancreas, spleen, lung and red blood cells, so a raised AST does not by itself point to the liver.
It is part of routine liver panels and is almost always read next to ALT. Labcorp notes that when a raised AST comes from the liver, it usually reflects injury to liver cells rather than blocked bile flow.
How it is made and regulated
Where it is made
AST comes in two forms, one in the cell fluid and one in the mitochondria; measuring them separately has no established clinical use. Heart, liver and skeletal muscle hold the most.
What controls it
Blood AST reflects cell damage in any AST-rich tissue. After a heart attack it begins to rise within 6-8 hours, peaks within two days and returns to normal by the fourth or fifth day; in liver disease it tracks liver-cell injury.
How it travels in the blood
AST needs vitamin B6 (pyridoxal 5-phosphate) to work. About 90% of people with severe cirrhosis are B6-deficient, but in two small groups of B6-deficient patients (8 and 9 people), giving B6 did not raise AST significantly. Some lab methods add the co-factor to the reagent.
How long it lasts
AST is cleared from the blood faster than ALT, with a half-life of about 18 hours against 36 hours. An antibody-bound form called macro-AST stays in the blood much longer, which can keep AST high for no medical reason.
What it does
Its clinical value is as a marker. Its ratio to ALT, described by De Ritis in 1957, reflects the type and pace of liver disease: a raised ratio predicts fibrosis and cirrhosis in chronic hepatitis, alcohol use and fatty liver disease.
Reference ranges
Labcorp's AST test page does not print a range, so the Labcorp interval below is the one printed on its sample reports. Quest gives ranges by age and sex. Use the range printed on your report.
Labcorp (test 001123)
| Group | Range (U/L) |
|---|---|
| Adult females (sample report) | 0-40 |
| Adult males (sample report) | 0-40 |
Labcorp sample reports, labelled as such: test 001123 (adult female) and the 322000 metabolic panel (adult male, 2022) both print 0-40 IU/L. Labcorp's test page publishes no range.
Quest Diagnostics (test 822)
| Group | Range (U/L) |
|---|---|
| Males, 20 to 49 years | 10-40 |
| Males, 50 years and older | 10-35 |
| Females, 20 to 44 years | 10-30 |
| Females, 45 years and older | 10-35 |
Children and teens
| Group | Range (U/L) |
|---|---|
| Males, under 28 days | 3-51 |
| Females, under 28 days | 3-49 |
| Males, 28 days to 11 months | 3-65 |
| Females, 28 days to 11 months | 3-79 |
| Males, 1 to 3 years | 3-56 |
| Females, 1 to 3 years | 3-69 |
| Children, 4 to 6 years | 20-39 |
| Children and teens, 7 to 19 years | 12-32 |
Ranges as shown for Quest's East region. Quest rejects hemolyzed samples for this test.
The Labcorp interval comes from its sample reports, not its test page; check your own report. Quest's ranges are for its East region.
What raises it
| Factor | How | How much |
|---|---|---|
| AlcoholLifestyle | Chronic alcohol use raises AST, often more than ALT. Most heavy drinkers without severe liver disease still have an AST/ALT ratio of 1 or below; a ratio of 2 or more suggests advanced alcohol-related liver disease. Labcorp notes AST in alcoholic hepatitis is usually under 300 units/L. | AST/ALT ratio of 2 or above in 69% of patients with alcohol-related cirrhosis [2] [10] |
| Viral and other hepatitisCondition | Injured liver cells release AST. In acute viral hepatitis AST can peak at 500-3000 units/L, 10 times or more above the upper limit. | Peak 500-3000 units/L in acute viral hepatitis [2] |
| Heart attack and heart failureCondition | Damaged heart muscle releases AST, and congestion of the liver in heart failure raises it too. ALT usually stays near normal after a heart attack, which helps tell the source apart. | Rises within 6-8 hours of a heart attack and peaks within two days [3] [2] |
| Heavy exercise and muscle diseaseLifestyle | Skeletal muscle is rich in AST. Weightlifting, muscle trauma, dystrophies and myositis raise it; a high CK points to muscle as the source. | Raised for at least 7 days after a 1-hour weightlifting session in 15 healthy men [11] [2] [12] |
| MedicationsMedication | Many drugs raise AST, including isoniazid, phenothiazines, erythromycin, anabolic steroids, methyldopa and statins. Acetaminophen poisoning, especially in heavy drinkers, can push AST into the thousands. | Acetaminophen hepatotoxicity in heavy drinkers: AST 1960-29,700 units/L [2] [13] |
| Hemolysis (sample or disease)Physiology | Red cells contain AST. Hemolysis in the tube biases AST upward more than most tests, and hemolytic anemias raise it in the body. | Among 20 routine tests, AST was the third most affected by hemolysis (after LDH and uric acid) [14] [2] [3] |
| Macro-ASTCondition | AST bound into a large complex is cleared slowly, so it builds up with normal CK and ALT and no disease. Reported levels split into two groups, under and over 200 U/L. | Circulating half-life of about 3.3 or 19.8 days, against 0.7 days for normal AST [6] [2] |
| Celiac diseaseCondition | A raised AST was the most common liver-test abnormality in children and teens with celiac disease. | AST high in 38 of 132 patients (28.8%) at diagnosis [15] |
| Peptide drugs with label-listed risesPeptide | Pasireotide and the GnRH analogs list AST rises on their labels. See the peptide table below. | Pasireotide: AST increased in 9 of 162 patients (6%) in a Cushing disease trial [16] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Chronic kidney disease and dialysisCondition | AST runs lower in kidney failure (uremia) and lower again on dialysis; in one study it fell as serum creatinine rose. This can hide liver injury. | Mean 17.9 vs 20.4 IU/L in people with chronic kidney failure (no viral hepatitis) vs healthy people [17] [2] |
| Vitamin B6 deficiencyNutrition | AST needs vitamin B6 as a co-factor. Labcorp lists B6 deficiency as a correctable cause of low AST. | No published magnitude [2] [18] |
| Metronidazole and trifluoperazineMedication | Labcorp lists both drugs among causes of a low AST. | No published magnitude [2] |
| Fatty-liver treatment with GLP-1-based peptidesPeptide | Less liver fat brings AST down. See the peptide table below. | Survodutide 6.0 mg weekly: AST -27.9% vs -7.2% with placebo at 48 weeks [19] |
Peptides that affect AST
How each peptide in our library has been shown to affect AST, strongest evidence first. Falls mostly come from fatty-liver trials; rises mostly come from drug labels. "No clear effect" means AST was measured and did not change; "Unclear" means the results conflict or lack a control group.
| Peptide | Effect on AST | Size of effect | Evidence |
|---|---|---|---|
| Bivalirudin | Raises | Same study: AST higher after the procedure than at baseline with bivalirudin (p = 0.025); small absolute changeA small AST rise around coronary angiography in one single-center study. [20] | Human trials |
| Polymyxin B | Raises | Same cohort: AST increased in 5/46 (10.9%) on polymyxin B vs 9/32 (28.1%) on colistin sulfate (p = 0.051)An uncontrolled cohort of very ill patients; no untreated comparison group. [21] | Human trials |
| Cotadutide | Lowers | Greater AST reductions than placebo with 200 µg (P = 0.009) and 300 µg (P = 0.001) daily after 54 weeks in adults with type 2 diabetes and overweight or obesitySame phase 2b trial as the ALT result. [22] | Human trials |
| Erythropoietin (EPO) | Lowers | AST lower with 30,000 U than with hydrocortisone on day 0 (P = 0.041) and day 1 (P = 0.018) after liver surgery with the Pringle maneuverSame small surgical trial as the ALT result. [23] | Human trials |
| Exenatide | Lowers | AST lower than with intensive insulin (p < 0.001) after 12 weeks in 60 type 2 diabetes patients with obesity and NAFLD; also lower than metformin in a second 12-week trialSeen in people with fatty liver; the fall tracked weight loss. [24] [25] | Human trials |
| Human Relaxin-2 | Lowers | RELAX-AHF (acute heart failure), IV serelaxin: AST among hepatic-damage markers improved vs placebo through day 14; no figure in abstractIn acute heart failure, serelaxin limited the rise in liver-damage markers including AST. The abstract gives no AST figures. [26] | Human trials |
| Leptin | Lowers | Metreleptin in 55 people with lipodystrophy: baseline AST 71 ± 77 U/L fell by 33 ± 14 U/L over 3 yearsSeen in leptin-deficient lipodystrophy with fatty liver disease; not studied in people with normal leptin. [27] [28] | Human trials |
| Mazdutide | Lowers | Phase 2, Chinese adults with type 2 diabetes, 3-6 mg weekly for 20 weeks: AST reductions with all doses (supplementary table); one transient AST >3x ULN in the obesity trialAST fell with all mazdutide doses in a diabetes trial; size of the change is only in the supplement. [29] | Human trials |
| Semaglutide | Lowers | Meta-analysis of randomized trials in people with or at risk of MASH: AST WMD -3.85 U/L (95% CI -7.67 to -0.03)Lowers AST modestly in fatty-liver disease populations. [30] | Human trials |
| Survodutide | Lowers | SYNCHRONIZE-MASLD phase 3, 48 weeks: AST -27.9% vs -7.2% placeboLowered AST in adults with obesity and fatty liver disease. [19] | Human trials |
| Tirzepatide | Lowers | SYNERGY-NASH phase 2 (biopsy-proven MASH) pooled in a meta-analysis: AST mean difference -20.71% vs placebo (P<0.00001)Lowered AST in adults with MASH. [31] | Human trials |
| Carnosine | No clear effect | NEAT RCT: carnosine 2 g/day vs placebo for 12 weeks; AST measured with no effect on liver functionOral carnosine did not change AST in a placebo-controlled trial. [32] | Human trials |
| Colistin | No clear effect | Same cohort: AST did not change significantly (p > 0.1)Colistin is hard on the kidneys but did not move liver enzymes in this cohort. [33] | Human trials |
| Enfuvirtide | No clear effect | AST 23.45 to 23.73 U/L (p = 0.722) with 90 mg twice daily for 7 days in 12 healthy men (crossover vs placebo)No AST change in healthy volunteers. [34] [35] | Human trials |
| Liraglutide | No clear effect | Meta-analysis of 5 RCTs, 180 people with biopsy-proven NASH: AST mean difference -1.99 IU/L (-5.70 to 1.72), p = 0.29In NASH trials, liraglutide did not change AST significantly versus control. [36] | Human trials |
| Retatrutide | No clear effect | MASLD substudy, 48 weeks: baseline AST normal (23-25 IU/L); 4 mg arm -19.9% at week 24 (P=0.042) but no consistent change versus placeboAST, like ALT, did not change consistently versus placebo in this phase 2a fatty-liver substudy. [37] | Human trials |
| Tesamorelin | Unclear | Phase III data, HIV with abdominal obesity and baseline ALT/AST >30 U/L: VAT responders AST -3.8 vs +0.4 U/L in nonresponders over 26 weeks (P=0.04)AST fell only in treated people whose belly fat dropped (responders) and who started with raised enzymes. There is no placebo comparison for AST, so the effect of the drug itself is unclear. [38] | Human trials |
| Vasopressin | Unclear | Retrospective, 117 children in vasodilatory shock: higher AST with higher cumulative dose in noncardiac patients, but authors found no major effect on liver functionIn critically ill children, AST was higher with more vasopressin in one subgroup; overall liver function was not clearly affected. [39] | Human trials |
| Cetrorelix | Raises | Controlled ovarian stimulation trials: ALT, AST, GGT or alkaline phosphatase elevations in 1-2% of patients, up to 3 times the upper limit of normalAn uncommon, mild liver-enzyme rise listed on the FDA label; its clinical significance was not determined. [40] | FDA label |
| Daptomycin | Raises | "Aspartate aminotransferase increased" listed among reactions possibly or probably drug-related in adult skin-infection trialsUncommon; AST also rises when muscle is injured, which daptomycin can cause. [41] | FDA label |
| Degarelix | Raises | Transaminase and GGT increases in 10% vs 5% with leuprolide in the pivotal trial; in the extension study grade 1/2 transaminase rises in 47% and grade 3 in 1% (men with prostate cancer)The label reports AST and ALT together as transaminases. [42] | FDA label |
| Goserelin | Raises | AST elevations reported in under 1% of women given the 3.6 mg implant; the label says causality was not establishedRare and not proven to be caused by goserelin. [43] | FDA label |
| Leuprolide | Raises | Lupron Depot 7.5 mg monthly and 30 mg 4-month trials (prostate cancer): increased AST recorded in at least 5% of patientsListed among lab abnormalities in men with advanced prostate cancer, where disease and other treatments make attribution hard. [44] | FDA label |
| Octreotide | Raises | Mycapssa label, postmarketing octreotide reports: "increased liver enzymes" (no frequency; test not specified)Postmarketing reports of raised liver enzymes; the label gives no rate and does not name AST separately, so the entry is shown for both ALT and AST. [45] | FDA label |
| Pasireotide | Raises | Phase III Cushing disease trial (162 patients): AST increased in 9 (6%); 5% had ALT or AST >3x ULN; mean rises returned to baseline by month 4Usually transient elevations reported in the pasireotide label. [16] | FDA label |
| Triptorelin | Raises | Trelstar trials: SGOT increases in >=10% of patients on 11.25 mg at Day 253; transaminase rises on 22.5 mg, mostly mild to moderateLabel lists mild-to-moderate AST rises with the longer-acting doses in men with prostate cancer. [46] | FDA label |
| PT-141 (Bremelanotide) | No clear effect | Bremelanotide trials: no imbalance in transaminase outliers vs placebo; one acute hepatitis case (transaminases >40x ULN) after 10 doses in the open-label extensionNo overall transaminase signal, but one unexplained hepatitis case is in the label. [47] | FDA label |
| IGF-1 (Insulin-Like Growth Factor 1) | Unclear | Increlex trials: mild AST and LDH elevations in a significant proportion of children both before and during treatment; none led to stoppingAST was mildly high before treatment as well as during it, so a drug effect is unclear. [48] | FDA label |
| Adiponectin | Lowers | Same rat model: AST 2436.8 ± 200.1 vs 3785.2 ± 183.5 U/L at 6 h (P < 0.01)Recombinant adiponectin reduced liver injury in a rat ischemia-reperfusion model. No human dosing data. [49] | Animal studies |
| Adrenocorticotropic Hormone (ACTH) | Lowers | Rats with TNF-induced injury: ACTH gel 10 IU/kg lowered serum AST (values shown only in figures)Lowered the liver-enzyme rise in a rat inflammatory injury model. No human liver data. [50] | Animal studies |
| Alpha-Melanocyte-Stimulating Hormone (α-MSH) | Lowers | Same mouse model: plasma AST 539.5 U/L with alpha-MSH 1.5 × 10^-6 mol/kg vs 6767.3 U/L in controls (P = 0.017); no protection at 3 × 10^-6 mol/kgIn a mouse acetaminophen liver-injury model, alpha-MSH lowered AST at one mid-range dose. No human data. [51] | Animal studies |
| BPC-157 | Lowers | Mice with radiation-induced liver injury (12 Gy), oral BPC-157: lower plasma ASTLowered AST in rodent liver-injury models. No human data on AST. [52] | Animal studies |
| GHRP-2 | Lowers | Blunted the LPS-induced rise in serum transaminases with 100 µg/kg i.p. in rats with endotoxemiaRat endotoxin model of liver injury only. [53] | Animal studies |
| Kisspeptin-10 | Lowers | Young male rats, 20 nmol/rat/day for 7 days (n=6/group): serum AST lower than saline controls (P<0.05)One small rat study: AST was lower after a week of kisspeptin-10. No human data on liver enzymes. [54] | Animal studies |
| Selank | Lowers | Male Wistar rats under chronic restraint stress, 100-1000 ug/kg intraperitoneally: serum AST reduced at all dosesRat stress study only: Selank lowered stress-raised AST. No human data. [55] | Animal studies |
| Adrenomedullin | No clear effect | Rats with hepatic ischemia-reperfusion: AST 378.8 with adrenomedullin alone vs 406.4 IU/L with vehicle; AM plus AMBP-1 lowered AST by 28%Adrenomedullin alone did not lower AST in rats; the drop needed its binding protein AMBP-1 given with it. [56] | Animal studies |
| ARA-290 | No clear effect | Pigs with renal ischemia-reperfusion given IV ARA-290: plasma AST no different from controls over 7 daysNo liver-enzyme change in pigs. No human data. [57] | Animal studies |
| Semax | Unclear | Rats: all doses lowered stress-raised AST after acute foot-shock stress, but AST rose at 5 ug/kg (acute) and 450 ug/kg (chronic) immobilization stressRat studies conflict on AST. No human data. [58] [59] | Animal studies |
What high or low results can mean
A high result
A high AST means cells rich in AST are being damaged: most often liver, but also muscle, heart or red cells. Comparing it with ALT and CK usually shows the source.
- Fatty liver disease
- Alcohol
- Viral hepatitis
- Medications, including acetaminophen overdose
- Heavy exercise or muscle disease
- Heart attack or heart failure
- Hemolysis, in the sample or the body
- Macro-AST
A low result
A low AST is rarely a concern, but it can go with kidney failure or vitamin B6 deficiency.
- Kidney failure (uremia) or dialysis
- Vitamin B6 deficiency
- Metronidazole or trifluoperazine
How the test works
| Sample | Serum (preferred) or lithium-heparin plasma at Labcorp, which does not accept oxalate, EDTA or citrate plasma and asks for the serum to be separated within 45 minutes. Quest prefers 1 mL of serum, accepts sodium or lithium heparin plasma, and rejects hemolyzed samples. |
|---|---|
| Fasting | Neither Labcorp nor Quest lists a fasting requirement for AST. |
| Timing | Avoid heavy exercise, especially weightlifting, before the test: in healthy men AST stayed raised for at least 7 days after one session. |
| Lab differences | Labcorp uses a kinetic method and Quest spectrophotometry. Hemolysis biases AST upward, which is why Quest rejects hemolyzed samples. Methods with added vitamin B6 (pyridoxal phosphate) are coded separately in LOINC (30239-8). |
| Retesting | Published within-person variation for AST ranges from 3.0% to 32.3% (median 11.9%), less than for ALT. |
| Labcorp order code | 001123: Aspartate Aminotransferase (AST/SGOT) |
| Quest Diagnostics order code | 822: Aspartate Aminotransferase (AST) |
| LOINC codes |
|
History
AST, then called SGOT, was first measured in blood as a test for heart attacks in 1954, and within a few years it was also being used to diagnose hepatitis.
- 1954LaDue, Wróblewski and Karmen report raised serum glutamic oxaloacetic transaminase (SGOT, now AST) in acute myocardial infarction. [63]
- 1955Karmen describes a spectrophotometric assay for SGOT in human serum, and with Wróblewski and LaDue reports transaminase activity in human blood. [64] [65]
- 1957De Ritis, Coltorti and Giusti publish an enzyme test for viral hepatitis from serum transaminase activities; the AST/ALT ratio still carries De Ritis's name. [66] [5]
- 2013A review of the De Ritis ratio recommends that labs reporting an abnormal ALT also report AST and the ratio, and use B6-supplemented assays in people at risk of deficiency. [5]
FAQ
Do I need to fast before an AST test?
Neither Labcorp nor Quest lists a fasting requirement for AST. Avoiding hard exercise matters more, since a workout can raise AST for days.
What is a normal AST level?
Labcorp's sample reports print 0-40 IU/L for adults. Quest's adult ranges are 10-40 U/L for men aged 20-49, 10-30 U/L for women aged 20-44, and 10-35 U/L for older men and women.
Why is my AST high but my ALT normal?
AST is also found in muscle, heart and red cells, so a hard workout, muscle injury or a hemolyzed sample can raise AST alone. Labcorp suggests checking ALT, GGT and CK; if those are normal, macro-AST is a harmless possibility.
What does the AST/ALT ratio mean?
Called the De Ritis ratio, it compares the two enzymes. ALT is usually higher in viral hepatitis and fatty liver. A ratio of 2 or more is typical of advanced alcohol-related liver disease, and a raised ratio in chronic liver disease predicts fibrosis and cirrhosis.
Can exercise raise AST?
Yes. In 15 healthy men, one hour of weightlifting raised AST, ALT, CK and myoglobin for at least 7 days. A healthy young man with very high transaminases from vigorous exercise was back to normal within weeks of stopping.
Can a heart attack raise AST?
Yes. AST begins to rise within 6-8 hours of a heart attack, peaks within two days and returns to normal by the fourth or fifth day.
What is macro-AST?
It is AST bound into a large complex that the body clears slowly, so it builds up without any disease. It typically shows as a raised AST with normal ALT and CK, and reported levels fall into groups under and over 200 U/L.
Can a blood-draw problem raise AST?
Yes. Red cells contain AST, so hemolysis in the tube pushes the result up. In a 2026 study it was among the tests most affected by hemolysis, and Quest rejects hemolyzed samples.
Can peptides affect AST?
GLP-1-based peptides lowered AST in fatty-liver trials: Semaglutide, Tirzepatide and Survodutide. Labels for Pasireotide, Degarelix, Triptorelin and Leuprolide list rises. Many other peptide results come from animal studies.
Can kidney disease change AST?
Yes, it lowers it. People with chronic kidney failure had lower AST than healthy people, and dialysis patients lower still, which can make liver injury harder to spot.
Sources: [17]
How much does AST vary between tests?
Published within-person variation ranges from 3.0% to 32.3%, with a median of 11.9%. A small change between two tests may be noise.
Sources: [62]
References
- Aminotransferases. In: Clinical Methods: The History, Physical, and Laboratory Examinations [Internet]. Butterworths; 1990. PMID 21250265
- Labcorp. Test 001123: Aspartate Aminotransferase (AST/SGOT). Methodology, use, limitations, specimen requirements and LOINC map. labcorp.com/tests/001123/aspartate-aminotransferase-ast-sgot
- Quest Diagnostics. Test code 822: Aspartate Aminotransferase (AST). Test directory entry (East region): methodology, specimen, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/822/aspartate-aminotransferase-ast?cc=PHP
- Rossouw JE, Labadarios D, Davis M, et al. Vitamin B6 and aspartate aminotransferase activity in chronic liver disease. S Afr Med J. 1978;53(12):436-8. PMID 675385
- Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013;34(3):117-30. PMID 24353357
- Rubin AS, Sass DA, Stickle DF. Distribution of serum concentrations reported for macroenzyme aspartate aminotransferase (macro-AST). Pract Lab Med. 2017;8:65-69. PMID 28856230
- Shaikh SM, Varma A, Kumar S, et al. Navigating Disease Management: A Comprehensive Review of the De Ritis Ratio in Clinical Medicine. Cureus. 2024;16(7):e64447. PMID 39139333
- Labcorp. Sample patient report, test 001123: AST (SGOT), adult female (printed reference interval 0-40 IU/L). files.labcorp.com/testmenu-d8/sample_reports/001123.pdf
- Labcorp. Sample patient report, test 322000: Comprehensive Metabolic Panel (14), adult male, reported 10/31/2022 (printed AST reference interval 0-40 IU/L). files.labcorp.com/testmenu-d8/sample_reports/322000.pdf
- Nyblom H, Berggren U, Balldin J, et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336-9. PMID 15208167
- Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65(2):253-9. PMID 17764474
- Khatri P, Neupane A, Sapkota SR, et al. Strenuous Exercise-Induced Tremendously Elevated Transaminases Levels in a Healthy Adult: A Diagnostic Dilemma. Case Reports Hepatol. 2021;2021:6653266. PMID 33777462
- Cadranel JF, Seddik M, Loric S, et al. [Statins: hepatotoxicity and monitoring]. Presse Med. 2009;38(5):717-25. PMID 19111435
- Yeganeh BS, Soleimani N, Zare S, et al. The Effect of Hemolysis on Biochemical Tests: Determining Interference Cutoffs and Managing Hemolytic Samples. J Anal Methods Chem. 2026;2026:9307894. PMID 41767878
- Saadah OI, Khayat A, Abusharifah O, et al. Liver function changes following the introduction of a gluten-free diet in patients with celiac disease. Clin Exp Hepatol. 2021;7(4):415-421. PMID 35402725
- SIGNIFOR (pasireotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
- Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2001;38(5):1009-15. PMID 11684554
- Youssef EM, Wu GY. Subnormal Serum Liver Enzyme Levels: A Review of Pathophysiology and Clinical Significance. J Clin Transl Hepatol. 2024;12(4):428-435. PMID 38638374
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. PMID 42252333
- Jia Q, Hu J, Ji W, et al. Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention. J Clin Transl Hepatol. 2021;9(4):477-483. PMID 34447676
- Wang J, Shah BK, Zhao J, et al. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect Dis. 2023;23(1):351. PMID 37231342
- Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021;44(6):1433-1442. PMID 34016612
- Kato M, Sawada T, Kita J, et al. Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver. World J Gastroenterol. 2010;16(38):4838-45. PMID 20939113
- Shao N, Kuang HY, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(6):521-9. PMID 24823873
- Fan H, Pan Q, Xu Y, et al. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol. 2013;57(9):702-8. PMID 24402015
- Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61(2):196-206. PMID 23273292
- Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922-32. PMID 22068254
- Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131-7. PMID 23439261
- Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024;47(1):160-168. PMID 37943529
- Kan R, Wang S, Meng X, et al. The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials. Diabetol Metab Syndr. 2025;17(1):439. PMID 41286982
- Zhao S, Tian F, Yu L, et al. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials. Intern Emerg Med. 2026;21(4):1343-1353. PMID 41917519
- Baba SP, Amraotkar AR, Hoetker D, et al. Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial. Amino Acids. 2024;56(1):55. PMID 39215872
- Wu Y, Jiang S, Li D, et al. Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases. Infect Dis Ther. 2024;13(1):141-154. PMID 38212555
- Barroso S, Morén C, González-Segura À, et al. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers. PLoS One. 2019;14(5):e0216712. PMID 31120908
- Enfuvirtide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID 31644169
- Malik A, Amjad W, Inayat F, et al. The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials. Prz Gastroenterol. 2023;18(1):100-109. PMID 37007754
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523
- Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2259. PMID 28832410
- Jerath N, Frndova H, McCrindle BW, et al. Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients. Intensive Care Med. 2008;34(7):1274-80. PMID 18350274
- CETROTIDE (cetrorelix acetate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
- Daptomycin for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d750e28d-1353-4671-66a3-ea4e49e81e7b
- FIRMAGON (degarelix) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
- ZOLADEX (goserelin implant) 3.6 mg, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
- LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
- MYCAPSSA (octreotide) delayed-release capsules, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d80bc6-bdfb-4908-93e7-aace447c8d1a
- TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
- VYLEESI (bremelanotide injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
- INCRELEX (mecasermin) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
- Zhang C, Liao Y, Li Q, et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One. 2013;8(6):e66382. PMID 23762489
- Si J, Ge Y, Zhuang S, et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int. 2013;83(4):635-46. PMID 23325074
- Blagaić V, Houra K, Turcić P, et al. The influence of alpha-, beta-, and gamma-melanocyte stimulating hormone on acetaminophen induced liver lesions in male CBA mice. Molecules. 2010;15(3):1232-41. PMID 20335976
- Huang BS, Huang SC, Chen FH, et al. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life Sci. 2022;310:121072. PMID 36228773
- Granado M, Martín AI, López-Menduiña M, et al. GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am J Physiol Endocrinol Metab. 2008;294(1):E131-41. PMID 17986630
- Aydin M, Oktar S, Yonden Z, et al. Direct and indirect effects of kisspeptin on liver oxidant and antioxidant systems in young male rats. Cell Biochem Funct. 2010;28(4):293-9. PMID 20517893
- Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bull Exp Biol Med. 2017;163(4):415-418. PMID 28853100
- Yang J, Wu R, Qiang X, et al. Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion. Ann Surg. 2009;249(2):310-7. PMID 19212187
- van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, et al. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med. 2013;11:9. PMID 23302512
- Bobyntsev II, Shepeleva OM, Kryukov AA, et al. [The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress]. Ross Fiziol Zh Im I M Sechenova. 2015;101(2):171-9. PMID 26012109
- Bobyntsev I, Kryukov AA, Shepeleva M, et al. [THE EFFECT OF ACTH-(4-7)-PGP PEPTIDE ON LIPID PEROXIDATION IN LIVER AND ACTIVITY OF SERUM TRANSAMINASES IN RATS UNDER ACUTE AND CHRONIC IMMOBILIZATION STRESS CONDITIONS]. Eksp Klin Farmakol. 2015;78(8):18-21. PMID 26591577
- Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. PMID 27995906
- LOINC 1920-8: Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/1920-8
- Carobene A, Braga F, Roraas T, et al. A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and γ-glutamyl transferase. Clin Chem Lab Med. 2013;51(10):1997-2007. PMID 24072574
- LADUE JS, WROBLEWSKI F, KARMEN A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science. 1954;120(3117):497-9. PMID 13195683
- KARMEN A. A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum. J Clin Invest. 1955;34(1):131-3. PMID 13221664
- KARMEN A, WROBLEWSKI F, LADUE JS. Transaminase activity in human blood. J Clin Invest. 1955;34(1):126-31. PMID 13221663
- DE RITIS F, COLTORTI M, GIUSTI G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70-4. PMID 13447217
Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.